Literature DB >> 8679103

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy.

G Nocentini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8679103     DOI： 10.1016/1040-8428(95)00187-5

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  25 in total

1.  Dehydration of ribonucleotides catalyzed by ribonucleotide reductase: the role of the enzyme.

Authors:  Nuno M F S A Cerqueira; Pedro Alexandrino Fernandes; Leif A Eriksson; Maria João Ramos
Journal:  Biophys J       Date:  2005-12-16       Impact factor: 4.033

2.  Cloning and characterization of the R1 and R2 subunits of ribonucleotide reductase from Trypanosoma brucei.

Authors:  A Hofer; P P Schmidt; A Gräslund; L Thelander
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Cellular delivery of nucleoside diphosphates: a prodrug approach.

Authors:  S H Kang; A K Sinhababu; J G Cory; B S Mitchell; D R Thakker; M J Cho
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

Review 4.  Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

Authors:  David Dingli; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

5.  Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.

Authors:  Ping Chen; Josephine Aimiuwu; Zhiliang Xie; Xiaohui Wei; Shujun Liu; Rebecca Klisovic; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2010-12-30       Impact factor: 4.009

6.  The conserved Lys-95 charged residue cluster is critical for the homodimerization and enzyme activity of human ribonucleotide reductase small subunit M2.

Authors:  Xinhuan Chen; Zhijian Xu; Lingna Zhang; Hongchuan Liu; Xia Liu; Meng Lou; Lijun Zhu; Bingding Huang; Cai-Guang Yang; Weiliang Zhu; Jimin Shao
Journal:  J Biol Chem       Date:  2013-11-19       Impact factor: 5.157

Review 7.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

8.  A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Authors:  Bingsen Zhou; Leila Su; Shuya Hu; Weidong Hu; M L Richard Yip; Jun Wu; Shikha Gaur; D Lynne Smith; Yate-Ching Yuan; Timothy W Synold; David Horne; Yun Yen
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

9.  Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access.

Authors:  Arijit Basu; Barij N Sinha
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

10.  A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.

Authors:  Natasha B Leighl; Scott A Laurie; Xueyu E Chen; Peter Ellis; Frances A Shepherd; Jennifer J Knox; Glenwood Goss; Ronald L Burkes; Gregory R Pond; Christopher Dick; Yun Yen; James A Zwiebel; Malcolm J Moore
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.